TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Rating of "Buy" by Brokerages

Key Points

• TScan Therapeutics, Inc. has received an average consensus rating of "Buy" from five research firms, with an average price objective of $7.80.
• Despite a recent 6.9% decline in share price, TScan's quarterly performance exceeded analysts' expectations, reporting $2.17 million in revenue against a consensus of $1.62 million.
• Insider activity is notable, as major shareholder Lynx1 Capital Management LP increased their stake by 25.92% after purchasing over 1.38 million shares at $1.20 each.

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have earned an average recommendation of "Buy" from the five research firms that are covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $7.80.

A number of equities research analysts have commented on TCRX shares. Needham & Company LLC reissued a "buy" rating and issued a $9.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, April 8th. Wall Street Zen raised shares of TScan Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. HC Wainwright dropped their price objective on shares of TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Wedbush restated an "outperform" rating and issued a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, May 6th.

TScan Therapeutics Trading Down 6.9%

Shares of NASDAQ:TCRX opened at $1.62 on Friday. TScan Therapeutics has a 52 week low of $1.02 and a 52 week high of $6.81. The company's 50 day moving average is $1.64 and its two-hundred day moving average is $1.71. The company has a current ratio of 8.55, a quick ratio of 8.55 and a debt-to-equity ratio of 0.15. The company has a market cap of $91.68 million, a PE ratio of -1.49 and a beta of 0.99.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 2,974.08% and a negative return on equity of 55.76%. The company had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.62 million. Equities analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Insider Activity

In related news, major shareholder Lynx1 Capital Management Lp bought 1,388,794 shares of the stock in a transaction dated Monday, May 19th. The stock was acquired at an average price of $1.20 per share, for a total transaction of $1,666,552.80. Following the acquisition, the insider owned 6,746,141 shares in the company, valued at approximately $8,095,369.20. This represents a 25.92% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 4.35% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Y Intercept Hong Kong Ltd acquired a new stake in TScan Therapeutics during the 2nd quarter worth $111,000. Vanguard Personalized Indexing Management LLC acquired a new stake in TScan Therapeutics during the 2nd quarter worth $29,000. Goldman Sachs Group Inc. boosted its stake in TScan Therapeutics by 6.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company's stock worth $235,000 after purchasing an additional 9,676 shares during the period. Checkpoint Capital L.P. boosted its stake in TScan Therapeutics by 14.9% during the 1st quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company's stock worth $2,784,000 after purchasing an additional 261,663 shares during the period. Finally, BVF Inc. IL boosted its stake in TScan Therapeutics by 63.6% during the 1st quarter. BVF Inc. IL now owns 4,889,474 shares of the company's stock worth $6,747,000 after purchasing an additional 1,900,000 shares during the period. Institutional investors and hedge funds own 82.83% of the company's stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.